Latest Period
Q2 2026
Security Snapshot
ArriVent BioPharma, Inc. - Common Stock (AVBP) Institutional Ownership
CUSIP: 04272N102
13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026
Institutions Reporting
156
Shares (Excl. Options)
46,103,756
Price
$34.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AVBP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 46,103,756
- Total 13F value
- $1,601,069,444
- Portfolio coverage rank
- 0.01%
- Share change
- +4,020,900
- Value change
- +$151,200,946
- Number of holders
- 156
- Shares outstanding
- 46,795,294
- SEC-reported price per share
- $28.22
- Insider filing price
- $28.22
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AVBP - ArriVent BioPharma, Inc. - Common Stock is tracked under CUSIP 04272N102.
- 156 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 138 to 156 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $969,468,905 to $1,601,069,444.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 156 institutions filings for Q2 2026.
Security key
04272N102
Latest holder period
Q2 2026
13F holders
156
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
AVBP full holder history
ArriVent BioPharma, Inc. SEC filings
ArriVent BioPharma, Inc. company facts
ArriVent BioPharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04272N102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
AVBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INFINITUM ASSET MANAGEMENT, LLC | 9.9% | 0% | $90,602,588 | +$15,488,850 | 4,123,923 | +21% | INFINITUM ASSET MANAGEMENT, LLC | 31 Dec 2025 |
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 9.5% | $86,322,700 | 3,929,117 | Hillhouse Investment Management, Ltd. | 31 Dec 2025 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.9% | $75,183,720 | 3,412,788 | Suvretta Capital Management, LLC | 30 Jun 2025 | |||
| BlackRock, Inc. | 6.8% | +20% | $110,545,459 | +$29,971,553 | 3,182,080 | +37% | BlackRock, Inc. | 30 Jun 2026 |
| ORBIMED ADVISORS LLC | 7.5% | $66,692,036 | 3,027,328 | ORBIMED ADVISORS LLC | 11 Aug 2025 | |||
| FMR LLC | 6.8% | -20% | $82,189,593 | -$10,666,113 | 3,016,132 | -11% | FMR LLC | 31 Mar 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 5.4% | $40,491,643 | 2,195,014 | HBM Healthcare Investments (Cayman) Ltd. | 08 Oct 2025 | |||
| Octagon Capital Advisors LP | 4.9% | $36,365,946 | 1,971,054 | Octagon Capital Advisors LP | 30 Sep 2025 | |||
| VANGUARD GROUP INC | 4.5% | -9.6% | $37,611,688 | -$3,224,708 | 1,869,266 | -7.9% | The Vanguard Group | 31 Dec 2025 |
| Sofinnova Venture Partners IX, L.P. | 4.1% | $35,767,532 | 1,696,752 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 31 Dec 2025 |
As of 30 Jun 2026, 156 institutional investors reported holding 46,103,756 shares of ArriVent BioPharma, Inc. - Common Stock (AVBP). This represents 99% of the company’s total 46,795,294 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
88%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 9.6% | 4,515,531 | +2.6% | 3.3% | $156,869,547 |
| INFINITUM ASSET MANAGEMENT, LLC | 9.5% | 4,438,384 | +7% | 16% | $154,189,460 |
| HHLR ADVISORS, LTD. | 8.4% | 3,929,117 | 0% | 16% | $136,497,525 |
| BlackRock, Inc. | 6.9% | 3,250,396 | +28% | 0% | $112,918,757 |
| ORBIMED ADVISORS LLC | 6.5% | 3,027,328 | 0% | 2% | $105,169,375 |
| FMR LLC | 5.9% | 2,778,959 | -7.9% | 0% | $96,541,033 |
| Octagon Capital Advisors LP | 4.2% | 1,971,054 | 0% | 6.3% | $68,474,416 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 1,774,873 | +16% | 0% | $61,659,088 |
| Sofinnova Investments, Inc. | 3.6% | 1,696,752 | 0% | 3.1% | $58,945,164 |
| STATE STREET CORP | 3.6% | 1,692,986 | +19% | 0% | $58,814,334 |
| Vivo Capital, LLC | 3.6% | 1,682,097 | +90% | 5.3% | $58,436,050 |
| NOVO HOLDINGS A/S | 3.2% | 1,500,000 | -23% | 3% | $52,110,000 |
| General Catalyst Group Management, LLC | 3.2% | 1,494,786 | 0% | 28% | $51,928,866 |
| Logos Global Management LP | 2.1% | 1,000,000 | +186% | 1.5% | $34,740,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 972,626 | +21% | 0% | $33,795,640 |
| D. E. Shaw & Co., Inc. | 1.9% | 872,011 | +136% | 0.02% | $30,293,662 |
| GOLDMAN SACHS GROUP INC | 1.8% | 853,723 | +0.03% | 0% | $29,658,337 |
| HSG Holding Ltd | 1.4% | 663,308 | 0% | 1.9% | $23,043,320 |
| Point72 Asset Management, L.P. | 1.2% | 566,796 | -24% | 0.03% | $19,690,493 |
| MILLENNIUM MANAGEMENT LLC | 0.94% | 438,664 | +3% | 0.01% | $15,239,187 |
| UBS Group AG | 0.94% | 438,594 | -9.8% | 0% | $15,236,756 |
| Balyasny Asset Management L.P. | 0.85% | 395,447 | -7.2% | 0.03% | $13,737,829 |
| AMERIPRISE FINANCIAL INC | 0.82% | 381,589 | +112% | 0% | $13,256,401 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.72% | 335,320 | +32% | 0% | $11,649,017 |
| NORTHERN TRUST CORP | 0.71% | 332,753 | +24% | 0% | $11,559,840 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q2 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 46,103,756 | $1,601,069,444 | +$151,200,946 | $34.74 | 156 |
| 2026 Q1 | 42,089,344 | $969,468,905 | +$42,325,450 | $23.07 | 138 |
| 2025 Q4 | 40,108,234 | $810,286,038 | +$21,067,734 | $20.12 | 122 |
| 2025 Q3 | 38,570,342 | $712,380,900 | +$89,390,684 | $18.45 | 104 |
| 2025 Q2 | 33,625,800 | $732,036,140 | +$99,572,817 | $21.77 | 96 |
| 2025 Q1 | 29,075,127 | $539,323,391 | +$6,162,682 | $18.49 | 82 |
| 2024 Q4 | 28,465,885 | $757,455,987 | +$26,598,551 | $26.64 | 80 |
| 2024 Q3 | 25,909,614 | $612,333,484 | +$70,385,573 | $23.50 | 68 |
| 2024 Q2 | 20,990,668 | $389,375,916 | -$3,300,286 | $18.55 | 53 |
| 2024 Q1 | 21,851,940 | $388,890,872 | +$388,416,714 | $17.86 | 53 |